Development of an S-1 dosage formula based on renal function by a prospective pharmacokinetic study

BACKGROUND: S-1 is an oral anticancer drug, containing tegafur (a prodrug of 5-fluorouracil, 5-FU), 5-chloro-2,4-dihydroxypyridine, and potassium oxonate. As renal dysfunction is known to increase exposure of 5-FU following S-1 administration, the incidence of severe adverse reactions is increased i...

Descripción completa

Detalles Bibliográficos
Autores principales: Booka, Eisuke, Imamura, Chiyo K., Takeuchi, Hiroya, Hamamoto, Yasuo, Gomi, Daisuke, Mizukami, Takuro, Ichiyama, Takashi, Tateishi, Kazunari, Takahashi, Tsunehiro, Kawakubo, Hirofumi, Soejima, Kenzo, Boku, Narikazu, Tanigawara, Yusuke, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906077/
https://www.ncbi.nlm.nih.gov/pubmed/26304171
http://dx.doi.org/10.1007/s10120-015-0536-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906077/
https://www.ncbi.nlm.nih.gov/pubmed/26304171
http://dx.doi.org/10.1007/s10120-015-0536-6

Ejemplares similares